That’s the conclusion of economist Glen Whitman and physician Raymond Raad, who write in Forbes:
Unfortunately, the health care bills moving through Congress could curtail medical innovation. Imposing price controls on drugs and treatments – or indirectly forcing their prices down by means of a “public option” or expanded public insurance programs – would reduce the incentive for innovators to develop new treatments.
Proposed reforms could also retard business model innovation – an area where innovation is weak. Congress has already used its control of Medicare to limit the growth of specialty hospitals. A nationally mandated insurance package would severely curtail innovation in payment methods and insurance products, which have the potential to improve the coordination and delivery of health care services.
The health care debate should address more than just covering the uninsured and controlling costs. When the U.S. generates medical innovations, the whole world benefits. That is a virtue of the American system that is not reflected in comparative life expectancy and mortality statistics.
The op‐ed is based on the authors’ Cato Institute policy analysis, “Bending the Productivity Curve: Why America Leads the World in Medical Innovation.”